KRAS and non-small cell lung carcinoma: The LOXO-RAS-20001 study (NCT04956640), a Phase I trial investigating LY3537982 in patients with advanced solid tumors harboring KRAS G12C mutations, reported a favorable safety profile across various solid tumors, including NSCLC, CRC, and PANC.